1. Introduction {#sec0001}
===============

Osteosarcoma (OS) is a highly malignant tumor of bone in children and adolescents [@bib0001], which accounts for about 2.4% of malignant tumors in children, and the incidence of OS is about 1--5 cases per million people per year \[[@bib0002],[@bib0003]\]. Most patients are diagnosed as OS under the age of 25 years, and there are more men than women among the OS patients \[[@bib0004],[@bib0005]\]. Both the metastasis and mortality rates of OS are high in clinic practice. About 20% OS patients were diagnosed with lung metastases at the time of the first diagnosis, and 80% OS metastases occur in the lung [@bib0006]. At present, the treatment of OS is mainly based on the combination of surgical resection and multiple chemotherapeutic drugs [@bib0007]. The average treatment rate of OS was 65% [@bib0008]. The average five-year survival rate of OS patients without metastasis was about 80% \[[@bib0009],[@bib0010]\]. 90% OS patients died of recurrence or metastasis due to the presence of tumor resistance, drug side effects and other causes, and the five-year survival rate of OS patients was only 20--30% [@bib0011], [@bib0012], [@bib0013]. So far, the molecular mechanism of OS remains unclear. Therefore, finding new molecular markers for early diagnosis and prognosis and therapeutic targets of OS is very important for improving the survival rate of OS patients. Encouragingly, some LncRNAs have recently been reported to play a key role in OS pathogenesis.

LncRNA is a class of non-coding RNAs that are longer than 200 nucleotides in length, with little or no protein coding capacity [@bib0014]. Recent studies showed that LncRNA is widely transcribed in mammalian genome and plays an important role in gene regulation, which is involved in biological processes such as tumor proliferation, invasion, metastasis, apoptosis and drug resistance \[[@bib0015],[@bib0016]\]. At present, the most important role of LncRNA may be associated with occurrence of cancers, and some studies have shown significant changes in LncRNA expression levels in colon, liver and lung cancers. Significantly high expressed LncRNA DLEU7-AS1 in patients with colon cancer promotes tumor invasion and metastasis through Wnt/β-catenin signaling pathway [@bib0017]. LncRNA HOTTIP can act as oncogenes to enhance the expression of anti-apoptotic factor Bcl-2 and promote chemotherapeutic resistance in small cell lung cancers by sponging miR-216a [@bib0018].LncRNA MEG3 inhibits the malignant progression of hepatocellular carcinoma by inhibiting PKM2 activity and β-catenin signaling pathway [@bib0019]. Recently, more and more literatures showed that LncRNAs are potential biomarkers for diagnosis and prognosis of OS.

So far, lots of researches have proved that LncRNA such as TUG1 [@bib0020], PVT1 [@bib0021] and ODRUL [@bib0022] are apparently highly expressed in OS patients. Jiang indicated that LncRNA DANCR can upregulate AXL expression by competitively sponging miR-33a-5p, enhance the function of cancer stem cells and promote the invasion and metastasis of OS [@bib0023]. Han found that LncRNA ATB is highly expressed in serum of OS patients, and its sensitivity and specificity are 83.33% and 90%, respectively [@bib0024]. Although many studies have assessed the correlation between LncRNA expression and OS prognosis, they are limited due to small sample sizes and different study qualities, and the prognostic value of LncRNA has not been agreed upon. Therefore, we conducted a systematic review and meta-analysis to quantitatively assess the relationship of LncRNAs expression with the prognosis and clinicopathology of OS patients.

2. Material and methods {#sec0002}
=======================

21. Search strategy {#sec0003}
-------------------

PubMed,EMbase,Web of Science,The Cochrane Library,SionMed,CNKI and WanFang databases were searched to identify eligible studies up to November 11, 2017. The search strategy used both MeSH terms and free-text words to increase the sensitivity of the search. The search terms included: ("Long non-coding RNA", "lncRNA", "LincRNA", "Long ncRNA", "Long intergenic non-coding RNA") AND ("Osteosarcoma", "Osteogenic Sarcoma", "Osteosarcoma Tumor") with the limit to human, detailed search strategy is attached to appendix.

2.2. Inclusion and exclusion criteria {#sec0004}
-------------------------------------

The eligible studies met the following criteria: (1) The clinical study of the expression of LncRNA in osteosarcoma; (2) Patients were confirmed osteosarcoma by pathological or histological examination; (3) qRT-PCR(Quantitative reverse transcription-polymerase chain reaction) was used to detect LncRNA expression in tissues or circulating blood of patients with osteosarcoma; (4) Studies provided sufficient information for extraction or calculation of the individual HR and 95%CI; (5) The association of LncRNAs with survivals was performed. Studies were excluded based on the following criteria: basic research of cell or animal experiment, duplicate articles, conference abstracts, case reports, review articles and letters.

2.3. Data collection and quality assessment {#sec0005}
-------------------------------------------

Two reviewers (Delong Chen and Meng Zhang) independently reviewed the eligible publications. The following data was extracted: surname of the first author, year of publication, the type of LncRNAs and expression, country, case number, cut-off value, sample type, outcome, clinicopathological features, outcome of study, HRs with their 95% CIs for OS or DFS and quality score. If the data was unavailable, we contacted study authors to request missing data. The information was extracted and recorded by using a standardized form. Two reviewers (Shan Jiang and Chi Zhou) independently assessed the quality of included studies by using Newcastle-Ottawa Quality Assessment Scale (NOS). If there are differences between the two reviewers, they can be resolved through discussion or finding another reviewer (Peng Chen).

2.4. Statistical analysis {#sec0006}
-------------------------

Review Manager 5.2 (The Cochrane Collaboration, Software Update, Oxford, UK) and stata12.0 (STATA Corporation, College Station, Texas, USA) were used for meta-analysis. The HRs and 95% CI were used to evaluate the association between LncRNAs and prognosis and clinicopathological features. HR \> 1 indicated that patients with upregulated LncRNA expression had poor prognosis. On the contrary, HR \< 1 meant that patients with decreased LncRNA expression had better prognosis. We directly extracted if HRs and 95% CIs were reported directly in the articles. Otherwise, HRs and 95% CIs were estimated from existing data or Kaplan--Meier curve using methods previously reported by Tierney et al. Heterogeneity among the eligible studies was assessed with I^2^ statistics and chi-square Q test. *P* \< 0.05 indicated statistically significant heterogeneity among studies, low heterogeneity: I^2 ^≥ 25%; moderate heterogeneity: I^2 ^≥ 50%; high heterogeneity: I^2 ^≥ 75%. Fixed-effects model was used when I^2 ^\< 50%. Otherwise, the random-effects model was used.

We conducted meta-regression analysis and subgroup analysis according to race, number of patients, HR availability, cut-off values and NOS scores. In order to verify the stability of the pooled results, we carried out sensitivity analysis. The publication bias was identified by Begg test and Egger test. *P* \< 0.05 was considered statistically significant.

3. Results {#sec0007}
==========

3.1. Study inclusion and characteristics {#sec0008}
----------------------------------------

As shown in the flow diagram ([Fig. 1](#fig0001){ref-type="fig"}), 478 articles were initially retrieved from PubMed,Embase, Web of Science, The Cochrane Library, SionMed, CNKI and WanFang databases. 177 duplicated articles were excluded. After the titles and abstracts were scanned, 188 irrelevant articles were removed. According to the inclusion and exclusion criteria, the full texts of remaining 113 articles were read for further evaluation and then 93 articles were excluded. Finally, 20 studies were included in the meta-analysis [@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], [@bib0031], [@bib0032], [@bib0033], [@bib0034], [@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044].Fig. 1Flow diagram of study selection process.Fig 1

The correlations between the expression levels of LncRNA and differences in clinicopathological features in osteosarcoma patients were described in [Table 1](#tbl0001){ref-type="table"}, including gender, age, tumor site, tumor size, tumor stage, metastasis, ALP and chemotherapy. The characteristics of 20 included studies were summarized in [Table 2](#tbl0002){ref-type="table"}. Most of these studies were performed in China (18/20), another two studies were performed respectively in Germany and Brazil. The number of patients in 20 studies ranged from 33 to 168. Specimens were composed of osteosarcoma tissue (*n* = 18) and serum (*n* = 2). Among these 20 articles, 20 provide data on correlation between LncRNA expression and overall survival (OS), 2 on correlation between LncRNA expression and disease free survival (DFS) or progression free survival (PFS), 1 on correlation between LncRNA expression and metastasis free survival (MFS), recurrence free survival (RFS) or event free survival (EFS).Table 1Comparison of *p* values of relationships between lncRNAs and clinicopathological features in osteosarcoma.Table 1AuthorYearLncRNAsCountryCase numberCut-offExpressionGenderAgeTumor siteTumor sizeTumor stageMetastasisALPChemotherapyJiang2017DANCRChina34NAup-regulatedNANANA\<0.05NA\<0.05NANAWen2017UCA1China151NAup-regulated0.5720.1990.8040.9070.0010.007NANACai2017HNF1A-AS1China72medianup-regulated0.2150.5340.1430.3110.0190.0090.1280.031O\'Leary2017PARTICLEGermany40NAup-regulated0.030NANANANA0.01NANAHuo2017MALAT1China46medianup-regulated0.7590.473NA0.0080.0580.000NANALi2017XISTChina145NAup-regulated0.8270.1020.8860.0090.0010.0090.704NAWang2017SOX2-OTChina138medianup-regulated0.7230.1150.1910.0360.0080.001NANAZhou2016CCALChina46medianup-regulated0.5550.2000.5020.1340.0170.006NANAPeng2016BANCRChina84medianup-regulated0.5090.5050.8140.0080.0040.0200.366NAJu2016BCAR4China168medianup-regulated0.3810.4940.9820.8100.0020.0010.1910.841Chen2016BCAR4China60medianup-regulated0.7950.4360.7540.0370.0410.028NANAMa2016TUG1China76fold-changeup-regulated0.8350.7010.0930.0110.0020.8020.2350.020Gao2016MALAT1China162medianup-regulated0.3350.2020.1930.3440.0000.001NANACong2016TUSC7China82fold-changedowm-regulated0.650.4730.627NA0.2940.087NANAUzan2016HULCBrazil33ROCup-regulated0.9990.0650.2740.67NA0.999NANAXia201691HChina67medianup-regulated0.4970.9270.114\<0.0010.0150.936NA0.023Li2016UCA1China135medianup-regulated0.5730.3390.5120.005\<0.0010.002NANATian2015MEG3China64mediandowm-regulated0.6140.3020.2810.0760.0060.011NANALi2015HOTTIPChina68medianup-regulated0.4650.2150.1610.1200.0030.016NANASun2015HULCChina78medianup-regulated0.4920.3520.6240.4960.0030.005NANA[^2]Table 2Characteristics of studies included in this meta-analysis.Table 2Table 2StudiesLncRNAsCountrySample TypeCase number (High/Low)MethodCut-offTumor stageoutcomeHR availabilityNOSJiang 2017DANCRChinaTissue34(17/17)qRT-PCRNANAOS,DFSDirectly7Wen 2017UCA1ChinaTissue151 (75/76)qRT-PCRNAIIA-IIIOS,DFSDirectly7Cai 2017HNF1A-AS1ChinaTissue72 (36/36)qRT-PCRmedianIIA-IIIOSDirectly6O\'Leary 2017PARTICLEGermanyTissue40 (23/17)qRT-PCRNANAOS,MFSIndirectly7Huo 2017MALAT1Chinaserum46 (18/26)qRT-PCRmedianI-IVOS,PFSIndirectly6Li 2017XISTChinaTissue145 (75/70)qRT-PCRNAI-IVOSDirectly7Wang 2017SOX2-OTChinaTissue138 (69/69)qRT-PCRmedianI-IIIOSDirectly7Zhou 2016CCALChinaTissue46 (23/23)qRT-PCRmedianI-IVOSDirectly7Peng 2016BANCRChinaTissue84 (42/42)qRT-PCRmedianIIA-IIIOSDirectly7Ju 2016BCAR4ChinaTissue168 (87/81)qRT-PCRmedianIIA-IIIOSDirectly7Chen 2016BCAR4ChinaTissue60 (30/30)qRT-PCRmedianI-IIIOS,RFSDirectly7Ma 2016TUG1ChinaTissue76 (41/35)qRT-PCRfold-changeI-IIIOS,PFSDirectly8Gao 2016MALAT1ChinaTissue162 (80/82)qRT-PCRmedianIIA-IIIOSDirectly7Cong 2016TUSC7ChinaTissue82 (13/69)qRT-PCRfold-changeearly-advancedOSDirectly7Uzan 2016HULCBrazilTissue33 (12/21)qRT-PCRROCNAOS,EFSIndirectly8Xia 201691HChinaserum67 (34/33)qRT-PCRmedianI-IIIOSDirectly8Li 2016UCA1ChinaTissue135 (68/67)qRT-PCRmedianI-IIIOSDirectly7Tian 2015MEG3ChinaTissue64 (32/32)qRT-PCRmedianI-IIIOSDirectly7Li 2015HOTTIPChinaTissue68 (34/34)qRT-PCRmedianIIA-IIIOSDirectly7Sun 2015HULCChinaTissue78 (39/39)qRT-PCRmedianIIA-IIIOSDirectly7[^3]

3.2. Prognostic value {#sec0009}
---------------------

Twenty studies comprising 1749 patients were included in final analysis to assess the effect of LncRNA expression on OS. As shown in [Fig. 2](#fig0002){ref-type="fig"}, the heterogeneity test indicated the existence of medium heterogeneity in OS (I^2 ^= 54%, *P* \< 0.00001), the pooled HR was 2.16 (95% CI: 1.68--2.79), which was calculated using random-effects model, the results suggested that a high LncRNA expression was significantly correlated with the poorer OS prognosis. The increased expressions of LncRNA UCA1 \[[@bib0025],[@bib0038]\], XIST [@bib0026], SOX2-OT [@bib0028], MALAT1 \[[@bib0029],[@bib0036]\], HNF1A-AS1 [@bib0030], PARTICLE [@bib0031], CCAL [@bib0032], 91H [@bib0033], HULC \[[@bib0034],[@bib0043]\], BCAR4 \[[@bib0035],[@bib0039]\], TUG1 [@bib0040], BANCR [@bib0041], MEG3 [@bib0042] and HOTTIP [@bib0044] indicated poorer prognoses of OS, on the contrary, the decreased expressions LncRNA DANCR [@bib0027] and TUSC7 [@bib0037] indicated better prognoses of OS. A total of 2 studies, including 185 patients, were included in the assessment of the effect of LncRNA expression on DFS ([Fig. 2](#fig0002){ref-type="fig"}). There was no statistically significant correlation between low expression of LncRNA and prognosis of OS (HR = 0.71, 95%CI: 0.05--9.53, *P* = 0.0003, I^2 ^= 92%).Fig. 2Forest plot for the association between LncRNA expression levels with overall survival and disease-free survival in osteosarcoma.Fig 2

We conducted meta-regression analysis and subgroup analysis according to race, number of patients, and calculation method of HR value, cut-off values and NOS scores ([Table 3](#tbl0003){ref-type="table"}). An additional file shows forest plot of HRs for subgroup analysis in more detail ([Fig. A.1](#fig0007){ref-type="fig"}). In the subgroup analysis, the fold change (HR = 0.97, 95% CI: 0.11--8.24) in cut-off value was not statistically significant, other results showed that expression of LncRNA was correlated with a worse OS prognosis. Meta regression analysis revealed that there were no significant correlations between all relevant stratified factors and the heterogeneity among studies (*P* value ranged from 0.08 to 0.957).Table 3General and subgroup analysis of the correlation between LncRNAs expression and overall survival.Table 3Table 3CategoriesNo. of studiesNo. of patientsHR(95%CI)for OSMeta-regression *P*-valueHeterogeneityI-squared(%)Chi-squared(P)OS2017492.16 (1.68--2.79)54%0.0003Race0.294Asian1816762.15 (1.63--2.82)58%0.001Not Asian2732.42 (1.25--4.7)0%0.53No. of patients0.121≥10068992.41 (1.78--3.27)4%0.39\<100147771.95 (1.4--2.73)62%0.001HR availability0.957Directly1716302.23 (1.67--2.99)54%0.004Indirectly31191.66 (1.16--2.37)13%0.31Cut-off values0.08Median1311882.11 (1.75--2.53)3%0.41Fold-change21580.97 (0.11--8.24)90%0.002Others54031.77 (0.71--4.4)77%0.002NOS scores0.147\>731762.92 (1.81--4.72)0%0.98≤71715732.05 (1.54--2.73)58%0.001

Of the total 20 LncRNAs, 4 (UCA1, BCAR4, HULC and MALAT1) were investigated in two studies. We found that the higher expressions of LncRNA UCA1 (HR = 2.70, 95% CI: 1.60--4.57), BCAR4 (HR = 2.58, 95% CI: 1.38--4.80), HULC (HR = 2.67, 95% CI: 1.45--4.92) and MALAT1 (HR = 2.41, 95% CI: 1.51--3.83), the poorer prognoses in osteosarcoma ([Fig. 3](#fig0003){ref-type="fig"}).Fig. 3Forest plots of studies evaluating hazard ratios of LncRNA UCAI,BCAR4,HULC and MALAT1 and overall survival of osteosarcoma patients.Fig 3

3.3. The correlation between LncRNAs and clinicopathological features {#sec0010}
---------------------------------------------------------------------

We evaluated the correlation between LncRNA expression and clinicopathological features of OS ([Table 4](#tbl0004){ref-type="table"}). LncRNA transcription level was significantly correlated with alkaline phosphatase (univariate analysis: HR = 2.13, 95% CI: 1.58--2.88, tumor size (univariate analysis: \< 8 / ≥ 8: HR = 1.97, 95% CI: 1.55--2.62) , metastasis (univariate analysis: yes/no: HR = 2.35, 95% CI: 1.69--3.26; multivariate analysis: yes/no: HR = 2.14, 95% CI:1.15--3.97) , distant metastasis(univariate analysis: presence/absence: HR = 5.03, 95% CI:3.78--6.69; multivariate analysis: presence/absence: HR = 4.02, 95% CI: 3.05--5.23) and Enneking stage (univariate analysis: yes/no: HR = 4.01, 95% CI: 3.08--5.23; multivariate analysis: IIA /IIB-III: HR = 3.2, 95% CI: 2.48--4.14), but not correlated with age (univariate analysis: ≤ 25 / \> 25: HR = 1.01, 95% CI: 0.78--1.3), gender (univariate analysis: female/male: HR = 1.15, 95% CI: 0.96--1.37),tumor site(univariate analysis: femur,tibia/elsewhere: HR = 1.15, 95% CI: 0.94--1.4),chemotherapy (univariate analysis: yes/no: HR = 1.45, 95% CI: 0.46--4.63) and tumor size (multivariate analysis: \< 8 / ≥ 8: HR = 1.28, 95% CI: 0.88--1.86) . An additional file shows forest plot for the association between overall survival time and clinicopathological features of patients in more detail ([Fig. A.2](#fig0008){ref-type="fig"} and [A.3](#fig0009){ref-type="fig"}). The results showed that the high expression of LncRNA was significantly correlated with the poorer OS prognosis (univariate analysis: HR = 2.95, 95% CI: 2.37--3.66; multivariate analysis: HR = 2.16, 95% CI: 1.68--2.79).Table 4Association between overall survival time and clinicopathological features of patients with osteosarcoma.Table 4Table 4clinicopathological ParametersstudiesUnivariate analysisstudiesMultivariate analysispooled HR(95%CI)P-valueI-squared(%)Chi-squared(P)Pooled HR(95%CI)P-valueI-squared(%)Chi-squared(P)Age(≤ 25 vs. \> 25)61.01(0.78--1.3)0.950%0.88Gender(Female vs. Male)111.15(0.96--1.37)0.120%0.97Tumor site (femur,tibia vs. elsewhere)111.15(0.94--1.4)0.1718%0.28ALP42.13(1.58--2.88)\<0.0000122%0.28Chemotherapy(yes vs. no)31.45(0.46--4.63)0.5386%0.0007Tumor size(\< 8 vs. ≥ 8)101.97(1.55--2.62)\<0.000010%0.6451.28 (0.88--1.86)0.264%0.02Metastasis(yes vs. no)42.35 (1.69--3.26)\<0.000010%0.9872.14 (1.15--3.97)0.0278%0.0002Distant metastasis(presence vs. absence)75.03(3.78--6.69)\<0.000010%0.8584.02 (3.05--5.23)\<0.00010%1Enneking stage(IIA vs. IIB--III)64.01 (3.08--5.23)\<0.000010%0.6473.2 (2.48--4.14)\<0.00010%0.63LncRNA expression112.95 (2.37--3.66)\<0.000010%0.93202.16 (1.68--2.79)\<0.0000154%0.002

In addition to significant heterogeneity among studies on correlation between high expression of LncRNA and chemotherapy (univariate analysis: yes/no: I^2 ^= 92%, *P* = 0.0007) , tumor size (multivariate analysis: \< 8 / ≥ 8: I^2 ^= 64%, *P* = 0.02) or metastasis (multivariate analysis: yes/no: I^2 ^= 78%, *P* = 0.0002) no significant heterogeneity was observed among the studies on correlation between high expression of LncRNA and other clinicopathological factors.

3.4. Publication bias and sensitivity analysis {#sec0011}
----------------------------------------------

The univariate and multivariate sensitivity analyses of OS showed that the individual study had no obvious influence on the whole study results, and the overall effect had a good stability ([Fig. 4](#fig0004){ref-type="fig"}.A and B). Both Begg\'s funnel plot and Egger\'s test were used to assess publication bias in the meta-analysis. The Begg\'s funnel plot of the pooled analysis in [Fig. 5](#fig0005){ref-type="fig"}.A--D was quite symmetric, and no publication bias was detected by Egger\'s test due to all *P*-values \> 0.05 ([Fig. 6](#fig0006){ref-type="fig"}.A--D).Fig. 4A--B Sensitivity analyses of the studies. (A) Multivariate analysis of overall survival; (B) Univariate analysis of overall survival.Fig 4Fig. 5A--D Begg\'s test for publication bias. (A) Multivariate analysis of overall survival (*P* = 0.127); (B) Tumor size (*P* = 1.000); (C) Tumor stage(*P* = 0.511); (D) Metastasis(*P* = 0.767).Fig 5Fig. 6A--D Egger\'s test for publication bias. (A) Multivariate analysis of overall survival (*P* = 0.951); (B) Tumor size(*P* = 0.631); (C) Tumor stage(*P* = 0.255); (D) Metastasis(*P* = 0.438).Fig 6

4. Discussion {#sec0012}
=============

Osteosarcoma has become a cancer with the highest mortality rate in children and adolescents, which has characteristics such as local corrosion and systemic metastasis. Although the five-year survival rate of OS patients without metastasis is 80%, the measures to treat the metastatic OS are very limited. LncRNA is widely involved in biological processes such as tumor proliferation, invasion, metastasis, apoptosis and drug resistance. Investigating the expression and clinical significance of LncRNA in OS patients can provide a basis for prevention, diagnosis and treatment of OS in clinic. Therefore, we conducted a meta-analysis to assess the relationship of LncRNAs expression with the prognosis and clinicopathology of OS patients.

Recent studies have shown that LncRNA is closely correlated with the OS prognosis. LncRNA FOXC2-AS1 can increase the expression of FOXC2 transcription factors and promote the drug resistance of Adriamycin and multidrug resistance of OS cells [@bib0045]. High LncRNA HOST2 expression is a biomarker of poor prognosis in OS patients, it affects the proliferation, migration, invasion and apoptosis of OS cells [@bib0046]. In this meta-analysis, a total of 20 studies comprising 1749 patients were included into the final analysis. Our results showed that high LncRNA expression was significantly correlated with a poorer prognosis in OS patients, which suggested that LncRNA plays an important role in the prognosis of OS. The same results were also found in the meta-analysis of other cancers such as colon cancer [@bib0047], cervical cancer [@bib0048] and prostate cancer [@bib0049]. However, there was moderate heterogeneity in multivariate analysis of overall survival (I^2 ^= 54%, *P* \< 0.00001), so we performed meta-regression analysis and subgroup analysis according to race, number of patients, HR availability, cut-off values and NOS scores. The results of Meta regression analysis showed that there were no significant correlations between these factors and the heterogeneity in this study, but there was still a significant heterogeneity in the subgroup analysis. In subgroup analysis, the median cut-off value (HR = 2.11, 95% CI: 1.75--2.53; heterogeneity: *P* = 0.41, I^2 ^= 3%) was significantly correlated with worse OS, but had no significant correlation with fold-change (HR = 0.97, 95% CI: 0.11--8.24; heterogeneity: *P* = 0.002, I^2 ^= 90%). Significant heterogeneity existed among studies of cut-off value, fold-change and OS, and the reason maybe that fewer cases were included in studies.

In the result of our study, high expressions of LncRNA UCA1, BCAR4, HULC and MALAT1 were reported in two literatures, which predicted a worse overall survival rate in OS patients. Li found that HIF-1α enhances the expression of LncRNA UCA1 and promotes the proliferation of OS cells by inhibiting the PTEN/Akt signaling pathway [@bib0050]. The study by Kong et al. showed that LncRNA HULC exerts a sponge effect on miR-122. Overexpression of miR-122 promotes PI3K/AKT, JAK/STAT and Notch signaling pathways, down-regulates HNF4G expression and enhances tumor invasion and metastasis [@bib0051]. LncRNA MALAT1 plays an important role in the OS progression through modulating the enhancers of zeste homolog 2 (EZH2). MALAT1 provides a new target for the treatment of OS by inhibiting E-cadherin expression and enhancing β-catenin expression [@bib0052]. Therefore, LncRNA UCA1, BCAR4, HULC, and MALAT1 are independent risk factors for poor prognosis in OS patients.

We also evaluated the relationship between LncRNA expression and the clinicopathological features of OS. An univariate analysis showed that LncRNA transcription levels were not associated with age (≤ 25/ \> 25), gender (male/female), tumor site (femur, tibia/elsewhere) and chemotherapy (yes/no), but were significantly correlated with ALP, tumor size (\< 8/ ≥ 8), tumor metastasis (yes/no), tumor distant metastasis (presence/absence) and Ennking stage (IIA /IIB-III). However, a multivariate analysis showed that there was no significant association between LncRNA transcription level and tumor size (\< 8/ ≥ 8), which may be one of the sources of heterogeneity.

In addition, there are still some deficiencies in this meta-analysis: (1) In order to reduce the bias caused by different methods of detecting LncRNA expression, we only included the studies using qRT-PCR method to detect LncRNA expression, which may bias the results due to different primers. (2) Different methods of HR extraction may also lead to bias. There were certain differences in HR and 95% CI between indirect and direct extractions. (3) The majority of populations were Asians included in this study, which may lead to biased results due to geographical differences. (4) Other factors such as different follow-up time and cut-off values will also result in bias.

In conclusion, this study shows that there is a significant correlation between the expression of LncRNA and the overall survival rate of OS patients, and it affects the prognosis of OS patients, suggesting that LncRNA may play an important role in the occurrence and development of OS. To further confirm our conclusion, a prospective high-quality study with a large sample size is needed to verify the role of LncRNA expression in the OS prognosis.

Appendices {#sec0018}
==========

 Fig. A.1Forest plot of HRs for subgroup analysis of the correlation between LncRNAs expression and overall survival**.** (A) Race; (B) Number of patients; (C) HR availability; (D) Cut-off values; (E) NOS scores.Fig 7Fig. A.2Forest plot for the association between overall survival time and clinicopathological features of patients with osteosarcoma in univariate analysis. (A) Age (≤ 25 vs. 25); (B) Gender (Female vs. Male); (C) Tumor site (femur,tibia vs elsewhere); (D) ALP; (E) Chemotherapy (yes vs. no); (F) Tumor size (\< 8 vs. ≥ 8); (G) Metastasis (yes vs. no); (H) Distant metastasis (presence vs. absence); (I) Enneking stage (IIA vs. IIB-III).Fig 8Fig. A.3Forest plot for the association between overall survival time and clinicopathological features of patients with osteosarcoma in multivariate analysis. (A) Tumor size (\< 8 vs. ≥ 8) ; (B) Metastasis (yes vs. no); (C) Distant metastasis (presence vs. absence); (D) Enneking stage (IIA vs. IIB--III).Fig 9
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